Medinol

Company Overview

Snapshot

Founded in December 1992 by Kobi Richter, Medinol operates with 51–200 employees. The company focuses on interventional cardiology and achieved a significant milestone in November 2017 with the FDA approval of its innovative EluNIR Drug-Eluting Stent System.

Business overview

Medinol is a Health Tech & Life Sciences company dedicated to advancing cardiovascular intervention. The company develops, manufactures, and markets the EluNIR elastomeric drug-eluting stent, which is recognized for its balance of flexibility, conformability, scaffolding, and low metal footprint. EluNIR features Flexx catheter technology, designed to enhance ease of delivery even in complex anatomies. Medinol serves the medical devices and drug delivery sectors, focusing on cardiology and cardiovascular markets globally.

Strategic signal

In November 2017, Medinol received FDA approval for its EluNIR Drug-Eluting Stent System, followed by its first U.S. commercial implants in January 2018. This regulatory clearance and subsequent market entry signal the company's successful navigation of stringent medical device approval processes and its readiness to compete in the highly regulated cardiovascular intervention market, validating its product's clinical efficacy and safety profile.

Company Intelligence Q&A

What is Medinol's primary focus?

Medinol is dedicated to the science of cardiovascular intervention, developing and manufacturing medical devices for this field.

What is the EluNIR Drug-Eluting Stent System?

The EluNIR is an elastomeric drug-eluting stent made from a thin cobalt-chrome alloy, designed for optimal balance between flexibility, conformability, scaffolding, and low metal footprint, offering uniform drug elution and surface quality.

When did Medinol's EluNIR stent receive European clearance?

In October 2017, Medinol's EluNIR Drug-Eluting Coronary Stent received European clearance.

When did the FDA approve Medinol's EluNIR Drug-Eluting Stent System?

In November 2017, Cordis and Medinol announced FDA approval of the innovative EluNIR Drug-Eluting Stent System.

When were the first U.S. commercial implants of the EluNIR Drug-Eluting Stent?

In January 2018, Cordis and Medinol announced the first U.S. commercial implants of the EluNIR Drug-Eluting Stent.